Ensuring Informed CML Care from Diagnosis Onward

Opinion
Video

Experts on chronic myeloid leukemia delve into the important role of informed shared decision-making in the optimal treatment of patients with CML.

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following:

  • As patients progress through their CML journey, how does the focus of shared decision-making evolve between the patient, caregiver, and healthcare team? What are some of the key challenges or changes you've observed in the patient, physician, and caregiver role over time?
    • What advice would you direct to patients and caregivers in navigating these changes?
Recent Videos
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
4 experts in this video
4 experts in this video